Catalyst Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.4M
Doctors Paid
4,850
Transactions
16,481
2024 Total
$1.2M
Payment Breakdown by Category
Research$2.1M (48.4%)
Food & Beverage$402,682 (9.2%)
Consulting$231,253 (5.3%)
Travel$202,508 (4.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 176 | 48.4% |
| Honoraria | $1.3M | 542 | 29.3% |
| Food and Beverage | $402,682 | 14,111 | 9.2% |
| Consulting Fee | $231,253 | 91 | 5.3% |
| Travel and Lodging | $202,508 | 560 | 4.6% |
| Space rental or facility fees (teaching hospital only) | $73,600 | 13 | 1.7% |
| Grant | $36,250 | 11 | 0.8% |
| Education | $25,136 | 975 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,550 | 2 | 0.1% |
Payments by Type
General
$2.3M
16,305 transactions
Research
$2.1M
176 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| LONG TERM SAFETY STUDY OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK ANTIBODY POSITIVE AND ACHR (ACETYLCHOLINE RECEPTOR) ANTIBODY POSITIVE MYASTHENIA GRAVIS | $634,026 | 0 | 49 |
| A RANDOMIZED PLACEBO-CONTROL PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS AND A SAMPLE OF ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS PATIENTS | $406,791 | 0 | 26 |
| A RANDOMIZED, PLACEBO-CONTROL, PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS, AND A SAMPLE OF ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS PATIENTS | $340,072 | 0 | 19 |
| AN OPEN-LABEL EXPANDED ACCESS PROTOCOL FOR AMIFAMPRIDINE PHOSPHATE TREATMENT IN PATIENTS WITH CONGENITAL MYASTHENIA SYNDROME (CMS) LAMBERT EATON MYASTHENIA SYNDROME (LEMS) AND DOWNBEAT NYSTAGMUS | $307,789 | 0 | 44 |
| AMIFAMPRIDINE PHOSPHATE FOR THE TREATMENT OF CONGENITAL MYASTHENIC SYNDROMES | $167,829 | 0 | 7 |
| AN OPEN-LABEL, EXPANDED ACCESS PROTOCOL FOR AMIFAMPRIDINE PHOSPHATE TREATMENT IN PATIENTS WITH CONGENITAL MYASTHENIA SYNDROME (CMS), LAMBERT EATON MYASTHENIA SYNDROME (LEMS), AND DOWNBEAT NYSTAGMUS | $108,406 | 0 | 19 |
| EXPANDED ACCESS STUDY AMIFAMPRIDINE PHOSPHATE IN LAMBERT-EATON MYASTHENIC SYNDROME (LEMS),CONGENITAL MYASTHENIC SYNDROME | $60,541 | 0 | 3 |
| LONG TERM SAFETY STUDY OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK POSITIVE ANTIBODY POSITIVE MYASTHENIA GRAVIS PATIENTS | $28,349 | 0 | 4 |
| PROOF OF CONCEPT STUDY OF THE EFFECT OF AMIFAMPRIDINE (FIRDAPSE) ON NEUROMUSCULAR TRANSMISSION IN PATIENTS WITH ONABOTULINUMTOXIN A (BOTOX, BTX-A) | $18,500 | 0 | 1 |
| REGISTRY STUDY TO OBSERVE LONG-TERM SAFETY OF VAMOROLONE (AGAMREE) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | $16,193 | 0 | 1 |
| EFFECTIVENESS, TOLERABILITY AND LONG-TERM MAINTENANCE OF PERAMPANEL USED FOR STATUS EPILEPTICUS MANAGEMENT | $14,000 | 0 | 1 |
| REAL-WORLD SAFETY AND EFFICACY OF PERAMPANEL USE IN ELDERLY | $6,474 | 0 | 1 |
| STUDY TO EVALUATE AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK-MG | $5,698 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Selim Benbadis, Md, MD | Neurology | Tampa, FL | $96,735 | $0 |
| Perry Shieh, Md, MD | Neuromuscular Medicine | Los Angeles, CA | $81,484 | $0 |
| Atiya Khan, M.d, M.D | Neurology | Fort Wayne, IN | $70,398 | $0 |
| Mazen Dimachkie, M.d, M.D | Neuromuscular Medicine | Kansas City, KS | $66,550 | $0 |
| Jesus Pina-Garza, Md, MD | Neurology | Nashville, TN | $59,690 | $0 |
| Steve Chung, M.d, M.D | Neurology | Phoenix, AZ | $53,140 | $0 |
| Matthew Holtzman, M.d, M.D | Clinical Neurophysiology | Wayne, MI | $51,018 | $0 |
| David King-Stephens, M.d, M.D | Neurology | Orange, CA | $48,520 | $0 |
| Daniel Lee, M.d, M.D | Neurology | Morehead, KY | $45,088 | $0 |
| Amanda Peltier, Md, MD | Neurology | Nashville, TN | $33,211 | $0 |
| Rossitza Chichkova, Md, MD | Neurology | Tampa, FL | $30,491 | $0 |
| Jeffrey Rosenfeld, Md, MD | Clinical Neurophysiology | Fresno, CA | $26,734 | $0 |
| Dr. Suraj Muley, Md, MD | Neurology | Phoenix, AZ | $25,213 | $0 |
| Ajay Gupta, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Cleveland, OH | $25,132 | $0 |
| Edward Smith, Md, MD | Pediatrics | Durham, NC | $21,858 | $0 |
| Dr. Robert Wechsler, Md, Phd, Faan, MD, PHD, FAAN | Clinical Neurophysiology | Boise, ID | $21,548 | $0 |
| Dr. Andrew Gordon, M.d, M.D | Neurology | Lake Barrington, IL | $20,028 | $0 |
| Dr. Migvis Monduy, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Miami, FL | $18,074 | $0 |
| Dr. David Gerber, M.d, M.D | Medical Oncology | Dallas, TX | $17,449 | $0 |
| Michael Chez, Md, MD | Neurology | Sacramento, CA | $16,946 | $0 |
| Dr. Aravindhan Veerapandiyan, Md, MD | Neurology with Special Qualifications in Child Neurology | Little Rock, AR | $16,694 | $0 |
| Dr. Dawn Eliashiv, M.d, M.D | Neurology | Los Angeles, CA | $16,505 | $0 |
| Dr. Andrew Zillgitt, Do, DO | Neurology | Garden City, MI | $15,945 | $0 |
| Amit Verma, Md, MD | Neurology | Houston, TX | $13,942 | $0 |
| Imad Najm, Md, MD | Neurology | Cleveland, OH | $13,331 | $0 |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. has made $4.4M in payments to 4,850 healthcare providers, recorded across 16,481 transactions in the CMS Open Payments database. In 2024, the company paid $1.2M. The top product by payment volume is FIRDAPSE ($2.9M).
Payments were distributed across 129 medical specialties. The top specialty by payment amount is Neurology ($946,310 to 2,001 doctors).
Payment categories include: Food & Beverage ($402,682), Consulting ($231,253), Research ($2.1M), Travel & Lodging ($202,508).
Catalyst Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.